2,235
Views
2
CrossRef citations to date
0
Altmetric
Editorial

The evolving role of time-limited targeted therapy in chronic lymphocytic leukemia

Pages 1015-1019 | Received 16 Apr 2020, Accepted 08 Sep 2020, Published online: 05 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

William G. Wierda, Thomas J. Kipps, Othman Al-Sawaf, Brenda Chyla, Juliana M. L. Biondo, Yong Mun, Yanwen Jiang & John F. Seymour. (2022) Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leukemia & Lymphoma 63:12, pages 2765-2784.
Read now
Stefano Molica, David Allsup, Valentina Gianfelici, Luciano Levato, Vincenzo Aiello, James Bailey & Aaron Polliack. (2021) Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 30:6, pages 621-633.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.